海新能科(300072.SZ):海新能科國際擬與鶴壁華石簽訂烴基生物柴油委託加工合同
格隆匯8月18日丨海新能科(300072.SZ)公佈,公司於2023年08月18日召開第五屆董事會第四十八次會議,審議通過了《關於公司全資子公司海新能科國際有限公司擬與鶴壁華石聯合能源科技有限公司簽訂委託加工合同暨關聯交易的議案》。
公司全資子公司海新能科國際有限責任HAIXIN ENERGY TECHNOLOGY INTERNATIONAL PTE.LTD.,簡稱“海新能科國際”)因業務需要擬與鶴壁華石聯合能源科技有限公司(簡稱“鶴壁華石”)簽訂烴基生物柴油委託加工合同,合同期限為18個月,預計合同期內加工生物原料總量約4萬噸,總合同金額不超過1.5億元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.